Does Rallies show Form 4 insider transactions for AGIO?

Yes. Rallies tracks AGIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AGIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AGIO. It does not provide personalized investment advice.

AGIO (Agios Pharmaceuticals, Inc.) Stock Analysis - Insider Trades

Agios Pharmaceuticals, Inc. (AGIO) is a publicly traded Healthcare sector company. As of May 21, 2026, AGIO trades at $28.50 with a market cap of $1.68B and a P/E ratio of -3.93. AGIO moved +2.72% today. Year to date, AGIO is +3.83%; over the trailing twelve months it is -5.54%. Its 52-week range spans $22.24 to $62.58. Analyst consensus is buy with an average price target of $39.40. Rallies surfaces AGIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AGIO stock inside the company?

Recent AGIO insider activity includes Burns James William sold 3.28K, Gheuens Sarah sold 2.94K, Jones Cecilia sold 3.14K, Milanova Tsveta sold 3.26K, and Viswanadhan Krishnan sold 2.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AGIO Key Metrics

Key financial metrics for AGIO
Metric	Value
Price	$28.50
Market Cap	$1.68B
P/E Ratio	-3.93
EPS	$-7.25
Dividend Yield	0.00%
52-Week High	$62.58
52-Week Low	$22.24
Volume	523.34K
Avg Volume	0
Revenue (TTM)	$66.05M
Net Income	$-422.60M
Gross Margin	90.04%

Recent AGIO Insider Trades

Burns James William sold 3.28K (~$113.85K) on Apr 2, 2026.
Gheuens Sarah sold 2.94K (~$102.05K) on Apr 2, 2026.
Jones Cecilia sold 3.14K (~$109.02K) on Apr 2, 2026.
Milanova Tsveta sold 3.26K (~$113.22K) on Apr 2, 2026.
Viswanadhan Krishnan sold 2.96K (~$102.71K) on Apr 2, 2026.

Latest AGIO News

Agios Q1 Mitapivat Sales Jump to $20.7M with 242 AQVESME Prescriptions — Apr 29, 2026
Agios Shares Plunge 25% After Novo’s Pill Cuts Crises by 27% — Apr 20, 2026
Agios Records 44 PYRUKYND Scripts, Eyes $1B Market and 2026 Catalysts — Mar 3, 2026
Agios Secures UAE Approval for Mitapivat in Transfusion and Non-Transfusion Thalassemia — Mar 2, 2026
Agios Reports $20M Q4 Revenues, AQVESME FDA Approval and $1.2B Cash — Feb 12, 2026

AGIO Analyst Consensus

8 analysts cover AGIO: 0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $39.40.

Common questions about AGIO

Who is trading AGIO stock inside the company?: Recent AGIO insider activity includes Burns James William sold 3.28K, Gheuens Sarah sold 2.94K, Jones Cecilia sold 3.14K, Milanova Tsveta sold 3.26K, and Viswanadhan Krishnan sold 2.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AGIO?: Yes. Rallies tracks AGIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AGIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AGIO. It does not provide personalized investment advice.